BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective upped by analysts at Needham & Company LLC from $14.00 to $15.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price points to a potential upside of 107.47% from the stock’s current price.

Several other research firms have also weighed in on BCRX. Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.17.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $7.23 on Monday. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The firm has a market capitalization of $1.50 billion, a P/E ratio of -11.85 and a beta of 1.76. The company’s 50 day simple moving average is $7.60 and its 200 day simple moving average is $7.60.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period last year, the company earned ($0.19) EPS. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. Sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. Xponance Inc. raised its holdings in BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after buying an additional 1,505 shares during the period. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after buying an additional 2,644 shares during the period. Creative Planning lifted its stake in BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after buying an additional 2,734 shares in the last quarter. Finally, SkyView Investment Advisors LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 3,000 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.